Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oaktree Acquisition Corp II Cl A (NY: OACB )

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, Jun 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 9.380 (3)
Ask (Size) 12.89 (5)
Prev. Close 9.380
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination
From Alvotech Holdings S.A.
Via Business Wire
Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech
From Oaktree Acquisition Corp. II
Via Business Wire

Performance

More News

Read More
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
From Alvotech Holdings S.A.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech Holdings S.A.
Via Business Wire
Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination
From Alvotech Holdings S.A.
Via Business Wire
Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange
From Alvotech Holdings S.A.
Via Business Wire
Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie
From Alvotech Holdings S.A.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022
Via Benzinga
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
Via Benzinga
Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
From Alvotech Holdings S.A.
Via Business Wire
Biosimilar Player Alvotech To Go Public Via $2.5B Oaktree SPAC Merger
Via Benzinga
Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company
From Alvotech Holdings S.A.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.